WELCOME

You're visitor number free hit counters login pageVisit the web design companies directory.

Since May 10th 2008


Initial R



Rauvolfia serpentina
Rheum officinale
Rhamnus frangula
Rhamnus purshiana
Rehmannia glutinosa


 

 

Herb`s Initial
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Click one of the letter above, then click on one of the herb on the left panel
or type a keyword below, and hit search button

 



Rhamnus frangula L. (Rhamnaceae)

Synonyms
Frangula alnus Mill., F. frangula (L.) Karst., F. vulgaris Borgh., Rhamnus alnus Mill., R. korolkowii Hort. Rehd., R. nemoralis Salisb., R. pentapetala Gilib. Ortega

Local names
Alder buck, alder buckthorn, alder dogwood, alno nero, alqueshra almoqadassa, amieiro preto, Amselbaum, arrow-wood, awsag aswad, bird cherry, black alder, black alder bark, black dog wood, bois à poudre, bois noir, bourdaine, Brechwegdorn, buckthorn, buckthorn bark, casca de amiero, corteccia di frangola, cortex frangulae, Cortex rhamni frangulae, corteza de arraclau, corteza de frangula, dog wood, écorce d’aune noir, écorce de bourdaine, écorce de frangule, Faulbaum, frangola, frangula, Gelbholzrinde, Glatter Wegdorn, glossy buckthorn, Grindholz, krusinnik, kulit frangula, kutyabengekéreg, Pulverholz, Pulverholzrinde, purging buckthorn, quishrul awsagel aswad, rhamnusbast, Schwarzholz, seyah-tusseh, shagrat hhabb esh shung, siâhtouseh, Spillbaum, sporkenhoutbast, vuilboombast, Zapfenholz, Zweckenholz

Description
A shrub, 3–5m high with non-thorny stalks and dark-red to purplishblue young branches spotted with greenish lenticels. Leaves alternate and ovate, entire or slightly sinuate along the margin, and have parallel secondary veins which curve as they meet the edge of the blade. Flowers small, greenish-white, hermaphrodite, pentamerous, arranged in axillary clusters of 2–3. Fruit a drupe, red at first, then black at maturity, with 2 or 3 seeds

Plant material used
dried bark

Chemical assays
Contains not less than 7.0% of glucofrangulins, calculated as glucofrangulin A, determined by spectrophotometry at 515nm. The high-performance liquid chromatography method reported for quantitative analysis of cascarosides can also be considered

Major chemical constituents
The active constituents are hydroxyanthraquinone glycosides (3–8%) consisting of monoglycosides and diglycosides of frangula emodin, with the diglycosides, glucofrangulins A and B, being the major compounds. The major monoglucosides are frangulins A and B. Other anthranoid derivatives present include emodin anthrone-6-O-rhamnoside (franguloside), as well as physcion and chrysophanol in glycosidic and aglycone forms. In the fresh bark, anthraquinones are not present, but exist as their reduced anthrone and dianthrone glycosides, which are converted by oxidation during drying and storage, or by accelerated heat and air treatment

Medicinal uses
Uses supported by clinical data
Short-term treatment of occasional constipation. As a single dose, for total intestinal evacuation before X-rays and other diagnostic examinations when electrolyte solutions alone are insufficient for adequate evacuation or the use of electrolyte solutions is not possible.

Uses described in pharmacopoeias and well established documents
As a cathartic.

Uses described in traditional medicine
Internally for treatment of diabetes and externally for skin irritations

Proven pharmacological activity
Animal studies
Laxative

Toxicity and overdose
As with other anthraquinone laxatives, the major symptoms of overdose are gripes and severe diarrhoea with consequent loss of fluid and electrolytes. Treatment of overdose should be supportive with generous amounts of fluid. Electrolyte levels should be monitored, particularly those of potassium. This is especially important in children and the elderly

Toxicity and overdose
As with other anthraquinone laxatives, the major symptoms of overdose are gripes and severe diarrhoea with consequent loss of fluid and electrolytes. Treatment of overdose should be supportive with generous amounts of fluid. Electrolyte levels should be monitored, particularly those of potassium. This is especially important in children and the elderly

Contraindications
Cortex Frangulae should not be administered to patients with intestinal obstruction and stenosis, atony, inflammatory diseases of the colon (such as ulcerative colitis, irritable bowel syndrome, Crohn disease), appendicitis, severe dehydration with water and electrolyte depletion, or chronic constipation. As with other stimulant laxatives, Cortex Frangulae is contraindicated in patients with cramps, colic, haemorrhoids, nephritis, or any undiagnosed abdominal symptoms such as abdominal pain, nausea or vomiting. Cortex Frangulae and other anthranoid laxatives are contraindicated during pregnancy because of their pronounced action on the large intestine and the lack of data on their toxicology. As anthranoid metabolites may appear in breast milk, Cortex Frangulae should not be used during lactation, since there are insufficient data to assess the potential for pharmacological effects in the breastfed infant. Use of Cortex Frangulae for children under the age of 12 years is contraindicated.

Warnings
Cortex Frangulae should only be used if no effect can be obtained through a change of diet or by the use of bulk-forming laxatives. Patients should also be warned that certain constituents of the bark are excreted by the kidney and may colour the urine orange, which is harmless. Cortex Frangulae and other stimulant laxatives should not be used by patients with abdominal pain, nausea or vomiting. The use of stimulant laxatives for longer than 2 weeks requires medical supervision. Rectal bleeding or failure to have a bowel movement after taking a laxative may indicate a serious condition. Chronic use may result in aggravation of constipation with laxative dependence and need for increased dosages, and disturbances of water and electrolyte balance (e.g. hypokalaemia). Chronic use may also lead to colonic dysfunction (atonicity) and melanotic pigmentation of the colonic mucosa (pseudomelanosis coli), which is harmless. Laxative abuse resulting in diarrhoea and consequent fluid and electrolyte losses (mainly of potassium) may cause albuminuria, haematuria, and cardiac and neuromuscular dysfunction. Neuromuscular dysfunction may arise particularly in the case of concomitant use of cardiotonic glycosides (e.g. digoxin, digitalis and strophanthin), diuretics, corticosteroids or liquorice root.

Precautions
General
Cortex Frangulae and other laxatives containing anthraquinone glycosides should not be used continuously for longer than 1–2 weeks, because of the possibility of electrolyte imbalance

Drug interactions
Increased intestinal transit time may result in reduced absorption of orally administered drugs. Electrolyte imbalances, such as hypokalaemia, may potentiate the effects of cardiotonic glycosides (e.g. digoxin, digitalis and strophanthus). Hypokalaemia resulting from long-term laxative abuse can also potentiate the effects of antiarrhythmic drugs (e.g. quinidine) that change sinus rhythm by affecting potassium channels. Hypokalaemia caused by drugs such as thiazide diuretics, adrenocorticosteroids or liquorice root may be exacerbated, and imbalance of other electrolytes may be aggravated.

Drug and laboratory test interactions
Anthranoid metabolites may not be detectable in faeces or urine by standard methods. Thus faecal excretion measurements may not be reliable (26). Urinary excretion of certain anthranoid metabolites may cause discoloration of the urine which is not clinically relevant, but may cause false positives in urinary urobilinogen tests and in estrogen measurements using the Kober procedure.

Carcinogenesis, mutagenesis, impairment of fertility
Although chronic use of anthranoid-containing laxatives has been hypothesized to play a role in colorectal cancer, no causal relationship has been demonstrated. Various Cortex Frangulae extracts have been shown to be genotoxic in several in vitro systems, resulting in bacterial mutation, and chromosomal aberration and DNA-repair defects in mammalian cells. However, no mutagenicity was observed in a gene mutation assay in mammalian cells. Frangula emodin was mutagenic in the Salmonella/microsome assay with S. typhimurium strain TA1537 only, but gave inconsistent results in gene mutation assays in mammalian cells. Frangula emodin was also a strong inducer of unscheduled DNA synthesis in primary rat hepatocytes, but gave negative results in the sister chromatid exchange assay.

Pregnancy: teratogenic effects
The teratogenic effects of Cortex Frangulae have not been evaluated. (See also Contraindications.)

Pregnancy: non-teratogenic effects
See Contraindications.

Nursing mothers
See Contraindications.

Paediatric use
See Contraindications.

Adverse reactions
Single doses of Cortex Frangulae may result in cramp-like discomfort of the gastrointestinal tract, which may require a reduction of dosage. Overdose can lead to colicky abdominal spasms and pain, as well as the formation of thin, watery stools. Long-term laxative abuse may lead to electrolyte imbalance (hypokalaemia and hypocalcaemia being the most important), metabolic acidosis, malabsorption of nutrients, weight loss, albuminuria and haematuria. Weakness and orthostatic hypotension may be exacerbated in elderly patients when stimulant laxatives are repeatedly used. Secondary aldosteronism may occur due to renal tubular damage after prolonged use. Steatorrhoea and protein-losing gastroenteropathy with hypoalbuminaemia have also been reported in laxative abuse. Pseudomelanosis coli has been observed in individuals taking anthraquinone laxatives for extended time periods. The pigmentation is harmless and usually reversible within 4–12 months after the drug is discontinued. Conflicting data exist on other toxic effects after long-term use such as damage to the autonomous nervous system of the colon. In incontinent patients using anthranoid laxatives, prolonged exposure of the skin to faeces may cause skin damage. Use of the fresh bark of Rhamnus frangula may cause severe vomiting, with possible abdominal spasms.

Dosage forms
Finely cut and powdered crude drug, powder, dried extract, liquid and solid preparations. Store in a tightly closed, light-resistant container for a maximum of 3 years.

Posology
(Unless otherwise indicated)
The correct dosage for the treatment of occasional constipation is the smallest dosage necessary to maintain a soft stool. Daily dosage: 0.5–2.5g crude drug taken directly or in a decoction; 0.5–2.5 ml 25% ethanol extract; all preparations standardized to contain 20–30 mg hydroxyanthracene derivatives calculated as glucofrangulin A; taken at bedtime, or in two divided doses, one in the morning and one at bedtime.

 

Herbal products and services


 

 

 

 

 

Copyright GREEN RING SOCIETY 2008